China’s Humanoid IPO Screen: Why Unitree Pulls Ahead of Pre-Profit Rivals

China's securities regulator has informally told some banks and investment firms to raise the approval bar for humanoid-robot IPOs, according to The Information. The reported “window guidance” asks applicants to show recurring revenue, a path toward narrower losses or substantive technological innovation. Reuters could not independently verify the guidance, and the China Securities Regulatory Commission has not published an operative rule. (The Information)

The reported shift should not be reduced to Unitree's 460% debut gain. The Information points to a broader set of concerns: a 2026 private-funding frenzy, a swelling IPO queue, weak post-listing performance at some robotics companies and copycat businesses with limited technical differentiation. (The Information)

For investors, the more useful question is which issuers would struggle most if those standards are already being applied.

The Information names GalBot, AgiBot, LimX Dynamics and Galaxea AI among humanoid companies that have filed listing paperwork. It reports $5.4 billion of funding into humanoid-robotics startups in the first half of 2026, versus $2.3 billion in all of 2025. (The Information)

A tougher IPO gate would not close the market to the sector. It would force weaker private companies to rely longer on private capital, strategic investors or slower spending while applicants with sales and technical differentiation retain a clearer route to public funding.

Unitree already has the commercial evidence regulators are said to want

Unitree is a useful benchmark because its filings show operating scale that many development-stage robotics companies lack.

Revenue reached RMB1.70 billion in 2025, up from RMB392.8 million in 2024 and RMB159.1 million in 2023. Humanoid robots produced RMB868 million in 2025, or 51.78% of revenue, and the company shipped more than 5,500 humanoid units that year. First-half 2026 revenue reached about RMB1.15 billion, up 48.5% year on year according to Shanghai Stock Exchange-hosted reporting. (Shanghai Stock Exchange)

The profit figures need more caution. A Shanghai Stock Exchange-hosted China Daily report says the prospectus showed RMB278.21 million of net profit in 2025 and RMB590.75 million of net profit attributable to the parent after excluding non-recurring items. A separate company statement cited in another SSE-hosted report gives RMB590 million of attributable profit excluding non-recurring items. (Shanghai Stock Exchange)

Adjusted parent profit exceeding reported net profit by that margin is unusual. The accessible secondary reproductions do not provide enough reconciliation to explain the gap safely, so the RMB590 million figure should not be treated as a clean comparable earnings measure until the underlying prospectus bridge is inspected.

The revenue and shipment evidence is sufficient for the narrower point. Unitree already looks materially more commercial than a startup whose valuation depends mostly on the humanoid label.

A tighter gate could increase scarcity for the names that pass

Unitree's shares rose more than fivefold on their Shanghai debut before falling about 45% from the post-listing high. Mech-Mind Robotics, another robotics-related issuer, was trading below its IPO price, according to The Information. (The Information)

Restricting weak issuers would cut public-market financing options for private robotics companies. At the same time, listed companies that satisfy the commercial and technical screen could become scarcer because fewer comparable securities reach the market.

That makes the reported guidance potentially negative for private financing optionality without making it uniformly negative for listed humanoid stocks.

China still has not published a formal humanoid IPO rule, and Reuters has not verified that the reported guidance is being applied consistently. If the standard described by The Information is in force, however, it would ration public capital according to commercial evidence and technical differentiation rather than shut the sector entirely.

Unitree shows the stronger end of that spectrum. The companies most exposed are those whose public-market case depends more on being classified as “humanoid” than on recurring customer revenue, narrowing losses or technology regulators can distinguish from dozens of competitors.

Sources

The Information, reported CSRC humanoid IPO guidance and applicant pipeline
Reuters, verification limitation and Unitree share performance
Shanghai Stock Exchange, Unitree revenue, shipment and profit figures
Shanghai Stock Exchange, Unitree humanoid revenue and IPO data